Kirk D. Malloy, PhD
Founder and Principal, BioAdvisors, LLC
Dr. Malloy has spent over 25 years in executive leadership positions in life sciences and in vitro diagnostics with Illumina, Inc., Biosite Inc. and QIAGEN Inc., and was most recently founder, chief executive officer and chairman of Verogen, Inc., until its acquisition in 2023. Dr. Malloy is currently the founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, molecular diagnostics and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as senior vice president and general manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013, he served as vice president of Global Customer Solutions; he was also vice president of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as senior director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Inc. and QIAGEN Inc. Dr. Malloy currently serves as a director for NanoString Technologies, Inc. (NASDAQ: NSTG) and DermTech, Inc. (NASDAQ: DMTK), as chairman of the board for cancer diagnostics company, Tagomics, and is a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Marine Science and Biology from the University of Miami, his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University.
Chairman of the Board